Equillium Inc (NAS:EQ)
$ 1.56 0.02 (1.3%) Market Cap: 55.00 Mil Enterprise Value: 23.43 Mil PE Ratio: 0 PB Ratio: 2.61 GF Score: 34/100

Equillium Inc at Jefferies London Healthcare Conference Transcript

Nov 15, 2022 / 08:35PM GMT
Release Date Price: $1.81 (+5.35%)
Roger Song
Jefferies - Analyst

Welcome, everyone. Welcome to day three Jefferies 2022 London Healthcare Conference. Next presenting company is Equillium. Representing the company is the CSO, Steve Connelly. Welcome.

Steve Connelly
Equillium, Inc. - Chief Scientific Officer

Thanks, Roger, and thank you to everybody attending here today, and thank you for the conference organizers for the opportunity to present. So I'm just going to go over a few slides, hit the high points that I think are important to investors about Equillium, and then I know Roger wants to go into some Q&A.

So Equillium, we are a company developing novel immunotherapies for autoimmune and inflammatory diseases. We largely target autoimmune diseases where we think there's severe unmet medical need or pockets where we believe we can bring a best-in-class therapy.

There are customary forward-looking statements and of course, some additional information about a pending transaction to acquire Metacrine. You can find more information here.

So why don't we dive

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot